Valrubicin is among the top four small-molecule drugs with the highest affinity for IGF2BP3, and it has been reported in clinical trials for superficial BCa chemotherapy, demonstrating that valrubicin is effective in ablating tumors remaining in the bladder after incomplete transurethral resection of bladder tumors and in preventing and delaying bladder tumor recurrence (34). Here, IGF2BP3 is linked to urinary bladder neoplasm.